Abstract

Introduction:
Tumours deploy advanced immune-evasion systems that suppress macrophage activation, disrupt antigen visibility, and create protective biochemical and biofield structures. Among the most critical mechanisms is Nagalase-mediated inhibition of GcMAF, a key macrophage-activating factor. Additional layers of stealth, including fibrin encapsulation, suppressive exosomes, miRNA signalling, and bioelectric/quantum field synchronisation, further impair host recognition. This study presents an integrated therapeutic model that restores immune visibility by targeting biochemical, structural, metabolic, and field-level tumour cloaking mechanisms.

Methods:
A multi-domain analytic framework was constructed by mapping tumour stealth pathways across enzymatic, fibrin-based, epigenetic, exosomal, miRNA, bioelectric, metabolic, and quantum-biological layers. Countermeasures were identified using literature-supported agents, biological activators, structured-water modulators, and field-disruption technologies. Key nodes of intervention included Nagalase suppression, GcMAF reconstitution, fibrin degradation, exosome interference, miRNA modulation, and coherence-breaking electromagnetic tools. A companion dataset (23×40 matrix) cross-mapped each stealth mechanism to therapeutic candidates, ECS interactions, GPCR/ TRPV1 signalling, and biofield destabilisation points.

Results:
Analysis identified Nagalase inhibition and GcMAF restoration as primary drivers of macrophage reactivation. Fibrin-targeting enzymes (nattokinase, serrapeptase) were predicted to dismantle tumour shielding, while mycological and botanical immunoregenerative agents enhanced antigen presentation. Exosome-disruptive compounds and polyphenol-based miRNA regulators reduced suppressive signalling. Electromagnetic and photonic tools demonstrated theoretical capacity for disrupting tumour coherence fields, improving immune visibility. Layered analysis revealed synergistic benefits when interventions were applied across biochemical and biofield domains simultaneously.

Conclusion:
Restoration of GcMAF activity represents a foundational strategy for reversing tumour invisibility. Integrating enzymatic, metabolic, immunological, and quantum-biological interventions yields a unified therapeutic pathway capable of disrupting multi-layered cancer stealth systems. This framework supports development of personalised, multi-modal immunotherapeutics and informs future clinical translation.